ArticleChild's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery2026
The application of programmable shunts in the management of hydrocephalus in pediatric patients.
Article in Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis study aims to analyze the use of programmable shunts in the treatment of hydrocephalus in pediatric patients, with particular emphasis on indications and treatment outcomes.
methodsA retrospective analysis was conducted of pediatric patients who underwent implantation of Medtronic™ Strata II programmable shunts for hydrocephalus between 2013 and 2023. Patients with tumor-related hydrocephalus were excluded.
resultsThe study population comprised 54 patients (22 girls and 32 boys) with a median age at programmable shunt implantation of 3.3 years (range 0.2-17.4 years) and a mean follow-up of 6.2 years (SD ± 2.9 years). Adjustable valves were implanted de novo in 22 patients (40.74%) and secondarily in 32 (59.26%). De novo implantation was primarily indicated for a significantly enlarged ventricular system (n = 17, 77.27%), while secondary implantation was mainly performed for overdrainage syndrome (n = 15, 46.88%). Reprogramming of opening-pressure settings was required in 44.44% of children (n = 24). Shunt revisions were performed in 24.07% of cases (n = 13), with all multiple revisions observed exclusively in patients with posthemorrhagic hydrocephalus (n = 7). At 10 years after shunt implantation, 90.9% of patients in the de novo group remained free from revision, compared with 59.9% in the secondary group (log-rank test, p = 0.023).
conclusionsThe analysis substantiated that programmable shunt implantation is an effective treatment for pediatric hydrocephalus. In most cases, initial valve settings were sufficient without the need for subsequent adjustments. Secondary implantation of a shunt and posthemorrhagic hydrocephalus etiology were associated with a higher risk of revision.
Indexed as
Identifiers
41831117What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.